Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1). / Bayarri-Olmos, Rafael; Kirketerp-Moller, Nikolaj; Pérez-Alós, Laura; Skjodt, Karsten; Skjoedt, Mikkel Ole; Garred, Peter.

In: Frontiers in Immunology, Vol. 9, 2238, 2018.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bayarri-Olmos, R, Kirketerp-Moller, N, Pérez-Alós, L, Skjodt, K, Skjoedt, MO & Garred, P 2018, 'Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)', Frontiers in Immunology, vol. 9, 2238. https://doi.org/10.3389/fimmu.2018.02238

APA

Bayarri-Olmos, R., Kirketerp-Moller, N., Pérez-Alós, L., Skjodt, K., Skjoedt, M. O., & Garred, P. (2018). Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1). Frontiers in Immunology, 9, [2238]. https://doi.org/10.3389/fimmu.2018.02238

Vancouver

Bayarri-Olmos R, Kirketerp-Moller N, Pérez-Alós L, Skjodt K, Skjoedt MO, Garred P. Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1). Frontiers in Immunology. 2018;9. 2238. https://doi.org/10.3389/fimmu.2018.02238

Author

Bayarri-Olmos, Rafael ; Kirketerp-Moller, Nikolaj ; Pérez-Alós, Laura ; Skjodt, Karsten ; Skjoedt, Mikkel Ole ; Garred, Peter. / Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1). In: Frontiers in Immunology. 2018 ; Vol. 9.

Bibtex

@article{4610b793e2e34d7ca78b5672a4693504,
title = "Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)",
abstract = "Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of complement with diverse functions spanning from host defense to embryonic development. CL-11 is found in the circulation in heterocomplexes with the homologous collectin-10 (CL-10). Abnormal CL-11 plasma levels are associated with the presence of disseminated intravascular coagulation, urinary schistosomiasis, and congenital disorders. Although there has been a marked development in the characterization of CL-11 there is still a scarcity of clinical tools for its analysis. Thus, we generated monoclonal antibodies and developed a quantitative ELISA to measure CL-11 in the circulation. The antibodies were screened against recombinant CL-11 and validated by ELISA and immunoprecipitation of serum and plasma. The best candidates were pairwise compared to develop a quantitative ELISA. The assay was validated regarding its sensitivity, reproducibility, and dilution linearity, demonstrating a satisfactory variability over a working range of 0.29-18.75 ng/ml. The mean plasma concentration of CL-11 in healthy controls was determined to be 289.4 ng/ml (range 143.2-459.4 ng/ml), highly correlated to the levels of CL/10/11 complexes (r = 0.729). Plasma CL-11 and CL-10/11 co-migrated in size exclusion chromatography as two major complexes of ~400 and >600 kDa. Furthermore, we observed a significant decrease at admission in CL-11 plasma levels in patients admitted to intensive care with systemic inflammatory response syndrome. By using the in-house antibodies and recombinant CL-11, we found that CL-11 can bind to zymosan independently of calcium by a separate site from the carbohydrate-binding region. Finally, we showed that CL-11/MASP-2 complexes trigger C4b deposition on zymosan. In conclusion, we have developed a specific and sensitive ELISA to investigate the ever-expanding roles of CL-11 in health and disease and shown a novel interaction between CL-11 and zymosan.",
keywords = "CL-11, collectin, complement system, lectin pathway, zymosan",
author = "Rafael Bayarri-Olmos and Nikolaj Kirketerp-Moller and Laura P{\'e}rez-Al{\'o}s and Karsten Skjodt and Skjoedt, {Mikkel Ole} and Peter Garred",
year = "2018",
doi = "10.3389/fimmu.2018.02238",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)

AU - Bayarri-Olmos, Rafael

AU - Kirketerp-Moller, Nikolaj

AU - Pérez-Alós, Laura

AU - Skjodt, Karsten

AU - Skjoedt, Mikkel Ole

AU - Garred, Peter

PY - 2018

Y1 - 2018

N2 - Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of complement with diverse functions spanning from host defense to embryonic development. CL-11 is found in the circulation in heterocomplexes with the homologous collectin-10 (CL-10). Abnormal CL-11 plasma levels are associated with the presence of disseminated intravascular coagulation, urinary schistosomiasis, and congenital disorders. Although there has been a marked development in the characterization of CL-11 there is still a scarcity of clinical tools for its analysis. Thus, we generated monoclonal antibodies and developed a quantitative ELISA to measure CL-11 in the circulation. The antibodies were screened against recombinant CL-11 and validated by ELISA and immunoprecipitation of serum and plasma. The best candidates were pairwise compared to develop a quantitative ELISA. The assay was validated regarding its sensitivity, reproducibility, and dilution linearity, demonstrating a satisfactory variability over a working range of 0.29-18.75 ng/ml. The mean plasma concentration of CL-11 in healthy controls was determined to be 289.4 ng/ml (range 143.2-459.4 ng/ml), highly correlated to the levels of CL/10/11 complexes (r = 0.729). Plasma CL-11 and CL-10/11 co-migrated in size exclusion chromatography as two major complexes of ~400 and >600 kDa. Furthermore, we observed a significant decrease at admission in CL-11 plasma levels in patients admitted to intensive care with systemic inflammatory response syndrome. By using the in-house antibodies and recombinant CL-11, we found that CL-11 can bind to zymosan independently of calcium by a separate site from the carbohydrate-binding region. Finally, we showed that CL-11/MASP-2 complexes trigger C4b deposition on zymosan. In conclusion, we have developed a specific and sensitive ELISA to investigate the ever-expanding roles of CL-11 in health and disease and shown a novel interaction between CL-11 and zymosan.

AB - Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of complement with diverse functions spanning from host defense to embryonic development. CL-11 is found in the circulation in heterocomplexes with the homologous collectin-10 (CL-10). Abnormal CL-11 plasma levels are associated with the presence of disseminated intravascular coagulation, urinary schistosomiasis, and congenital disorders. Although there has been a marked development in the characterization of CL-11 there is still a scarcity of clinical tools for its analysis. Thus, we generated monoclonal antibodies and developed a quantitative ELISA to measure CL-11 in the circulation. The antibodies were screened against recombinant CL-11 and validated by ELISA and immunoprecipitation of serum and plasma. The best candidates were pairwise compared to develop a quantitative ELISA. The assay was validated regarding its sensitivity, reproducibility, and dilution linearity, demonstrating a satisfactory variability over a working range of 0.29-18.75 ng/ml. The mean plasma concentration of CL-11 in healthy controls was determined to be 289.4 ng/ml (range 143.2-459.4 ng/ml), highly correlated to the levels of CL/10/11 complexes (r = 0.729). Plasma CL-11 and CL-10/11 co-migrated in size exclusion chromatography as two major complexes of ~400 and >600 kDa. Furthermore, we observed a significant decrease at admission in CL-11 plasma levels in patients admitted to intensive care with systemic inflammatory response syndrome. By using the in-house antibodies and recombinant CL-11, we found that CL-11 can bind to zymosan independently of calcium by a separate site from the carbohydrate-binding region. Finally, we showed that CL-11/MASP-2 complexes trigger C4b deposition on zymosan. In conclusion, we have developed a specific and sensitive ELISA to investigate the ever-expanding roles of CL-11 in health and disease and shown a novel interaction between CL-11 and zymosan.

KW - CL-11

KW - collectin

KW - complement system

KW - lectin pathway

KW - zymosan

U2 - 10.3389/fimmu.2018.02238

DO - 10.3389/fimmu.2018.02238

M3 - Journal article

C2 - 30323815

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 2238

ER -

ID: 218650150